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Abstract. Obstructive sleep apnea syndrome (OSAS) is associated with an elevated risk of cardiovascular events and stroke.
Matrix metalloproteinases (MMPs) are endopeptidases involved in extracellular matrix degradation and then in the develop-
ment and progression of cardiovascular diseases. Our aim was to evaluate plasma levels of gelatinases (MMP-2 and MMP-9)
and their tissue inhibitors (TIMP-1 and TIMP-2) in a group of subjects with OSAS. We enrolled 48 subjects (36 men and 12
women; mean age 49.7 ± 14.68 yrs) with OSAS diagnosed with a 1-night cardiorespiratory study and then we subdivided
these subjects into two subgroups according to the apnea/hypopnea index (AHI): Low (L = 21 subjects with AHI <30) and
High (H = 27 subjects with AHI >30). We measured plasma concentration of the gelatinases and their inhibitors using ELISA
kits. We observed a significant increase in plasma concentration of MMP-9, MMP-2, TIMP-1 and TIMP-2 in the entire group
of OSAS subjects and in the two subgroups, with higher levels in the H in comparison with the L subgroup. In the whole
group of OSAS subjects we also noted a significant decrease in MMP-9/TIMP-1 ratio in comparison with normal controls.
Only MMP-9 was significantly correlated with the severity of the disease, expressed as AHI, with the oxygen desaturation
index and also with the mean oxygen saturation. MMPs pattern is altered in OSAS and significantly influenced by the severity
of the disease; it probably contributes to the vascular remodeling that leads to the atherosclerotic disease and cardiovascular
complications.
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1. Introduction
The obstructive sleep apnea syndrome (OSAS) is a common sleep disorder characterized by repeated
airflow obstructions during sleep with consequent episodes of apnea or hypopnea and intermittent
arterial oxygen desaturation [8, 30]. The OSAS affects especially middle-aged and elderly subjects
and its prevalence is increasing worldwide [27]. The gold standard methodology for diagnosis of OSA is
the in-laboratory polysomnography, but the home testing with portable cardiorespiratory monitoring
is an accredited alternative [8]. The frequency of respiratory events during sleep is expressed as
apnea/hypopnea index (AHI), which defines OSAS severity [8]. The standard treatment for OSAS is
the continuous positive airway pressure (CPAP) therapy, which ideally suppresses the apneic events
[27].
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OSAS is independently associated with an increased risk of morbidity and mortality [28] consid-
ering that the most important complications are arterial hypertension, coronary artery disease, and
cerebrovascular accidents [7, 21, 37, 39]. Atherosclerosis is common in OSAS, and several studies
have demonstrated that the elevated mortality in OSAS is associated with the severity of the atheroscle-
rosis [33]. In OSAS subjects the carotid intima-media thickness is significantly increased compared to
controls [22] and a recent study has demonstrated that OSAS severity is correlated also with subclinical
coronary atherosclerosis [38].
The mechanisms leading to the development and the progression of atherosclerotic plaques involve
multiple factors, including oxidative stress, endothelial dysfunction, and inflammatory and immuno-
logic factors. The continued hypoxia-reoxygenation episodes have a key role in the pathogenesis of
the endothelial dysfunction in OSAS: the intermittent hypoxia may induce the production of reactive
oxygen species (ROS) that contribute to the generation of adhesion molecules, leukocyte activation,
and an enhanced systemic inflammation leading to endothelial damage [19].
Matrix metalloproteases (MMPs) are endopeptidases produced into the vascular wall, in particular by
macrophages, able to degrade several extracellular matrix proteins [1, 12]. Gelatinases A and B (MMP-
2 and -9) are responsible for IV type collagen, gelatin and laminin degradation, vasculature remodeling,
angiogenesis, inflammation and then they are involved in the atherosclerotic process [10, 24]. Once they
are secreted in the extracellular space, MMPs may be activated by several proteases, other MMPs, and
ROS, in particular peroxynitrite [1, 15, 16]. Some authors have described an overexpression of MMP-9
in older atherosclerotic lesions [20], responsible for a large remodeling characterized by fibrosis, matrix
degradation and angiogenesis, resulting in plaque instability and rupture [11, 20]. However, MMP-
2 seems to be associated with a more stable plaque phenotype and rare haemorrhages [11]. MMPs
activity is also regulated by the four tissue inhibitors of MMP (TIMPs): TIMP-1 inhibits especially
MMP-9 while TIMP-2 inhibits especially MMP-2 [23]. An altered expression of MMPs and TIMPs
has been observed in OSAS. Tazaki et al. observed a significant increase in MMP-9, but not in TIMP-1,
serum levels in obese OSAS subjects compared to obese controls [32]. In addition, they found higher
serum levels and activity of MMP-9 in subjects with moderate to severe OSAS than in subjects with
mild disease [32]. MMP-9 concentration and activity were significantly correlated with AHI, BMI and
inflammatory cytokines, such as IL-6 and TNF-α [32]. Similarly, Ye et al. [41] described elevated serum
levels of MMP-9 in OSAS subjects in comparison with obese controls, correlated with OSAS severity
and C-reactive protein levels. Differently, in children with OSAS no correlation between MMP-9 levels
and OSAS severity has been observed [14]. Volna´ et al. [35] evaluated both the gelatinases in OSAS
subjects and they observed a significant correlation only between MMP-9 and some polysomnographic
parameters, such as oxygen desaturation index (ODI) and mean oxygen saturation. Chuang et al. [3]
studied plasma levels of MMP-1, -2, -3, and -9 and of TIMP-1 and also plasma MMP-9 activity in OSAS
subjects subdivided according to the severity of the disease; they found only elevated concentration
and activity of MMP-9, especially after sleep. Tamaki et al. [31] observed in severe OSAS subjects an
increased production of MMP-9 by monocytes immediately after the sleep, significantly decreased by
long-term cPAP treatment. More recently, Vuralkan et al. [36] demonstrated a significant reduction of
MMP-9 serum levels in OSAS subjects who underwent uvulopalatal flap surgery, but no correlation
between post-operative MMP-9 and polysomnographic variables.
Previously we studied in subjects with OSAS the behaviour of nitric oxide metabolites (NOx)
and erythrocyte deformability [2] and the relationship between OSAS severity and oxidative stress,
examined as lipid peroxidation and protein oxidation [13]. In particular, we found a reduced red cell
deformability, an altered NOx plasma level in subjects with severe OSAS, and an increase in lipid and
protein oxidation, statistically correlated with the severity of OSAS [13]. Now our aim was to evaluate
plasma concentration of MMP-9, MMP-2, and their tissue inhibitors (TIMP-1 and TIMP-2) in a group
of subjects with OSAS.
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2. Materials and methods
We consecutively recruited 48 subjects (36 men and 12 women; mean age 49.7 ± 14.68 yrs) with
obstructive sleep apnea syndrome from those with suspected OSAS referred to our center. Clinical
history and physical examination were performed in all subjects and Epworth Sleepiness Scale (ESS)
was also given. OSAS was diagnosed after a 1-night cardiorespiratory sleep study: apneas were defined
as the cessation of airflow for ≥10 seconds and hypopneas were defined as a transient reduction of
breathing ≥50% with an oxygen desaturation of ≥3% or as a reduction of breathing ≥30% with an
oxygen desaturation of ≥4% for ≥10 seconds. Obstructive apneas and hypopneas were distinguished
from central events by the detection of respiratory efforts during the event. AHI was defined as the num-
ber of obstructive apneas and hypopneas per hour of sleep. Patients with an AHI ≥5 were considered
as OSAS and then they were subdivided according to the AHI value in two subgroups: Low (L = 21
subjects with AHI <30) and High (H = 27 subjects with AHI >30). Means and S.D. of age, BMI, waist
circumference, neck circumference, AHI, oxygen desaturation index (ODI), mean nocturnal SO2 and
mean heart rate (HR) are reported in Table 1 (Table 1); 23 of the OSAS subjects had arterial hyper-
tension, 10 subjects had diabetes mellitus and 6 had cardiovascular disease (history of myocardial
infarction or stroke). The control group consisted of 31 subjects (14 women and 17 men, mean age
41.3 ± 7.4 years) selected from the hospital staff; control subjects were free of medical diseases as
assessed by clinical history, physical examination, electrocardiography, and routine hematological and
urine analysis
All the subjects gave their informed consent before entering the study and the study was approved
by the Ethical Committee.
On fasting venous blood we evaluated plasma concentrations of gelatinases (MMP-2 and MMP-9)
and their inhibitors (TIMP-1 and TIMP-2) using respectively the Human MMP-2 ELISA and Human
MMP-9 ELISA kit (Boster Biological Technology, LTD) and the Human TIMP-1 ELISA and Human
TIMP-2 ELISA kit (Boster Biological Technology, LTD).
2.1. Statistical analysis
Data were expressed as means ± S.D. The statistical difference between the whole group of OSAS
subjects and control subjects was evaluated using the Student’s t test for unpaired data. The statisti-
cal difference among control subjects, L subgroup and H subgroup of OSAS subjects was evaluated
Table 1
Mean ± S.D. of age, anthropometric characteristics and OSAS parameters in the whole group of OSAS patients and in the
two subgroups with respectively mild and severe disease
All OSAS patients Mild OSAS Severe OSAS
Age (years) 49.7 ± 14.6 45.3 ± 14.4 52.8 ± 14.2
BMI (kg/m2) 35.4 ± 7.3 35.7 ± 8.5 35.1 ± 6.5
Waist circumference (cm) 118.8 ± 16.1 114.2 ± 14.5 122.5 ± 16.6
Neck circumference (cm) 44.4 ± 4.5 41.5 ± 3.2 46.6 ± 4.1∗∗∗
AHI 38.5 ± 25.7 15.1 ± 8.1 56.6 ± 18.9∗∗∗
mSO2 (%) 91.1 ± 3.7 93.4 ± 2.7 89.5 ± 3.4∗∗∗
ODI 39.3 ± 29.0 14.3 ± 9.4 55.4 ± 25.7∗∗∗
ESS 11.1 ± 5.1 9.2 ± 3.7 12.4 ± 5.6∗
∗p < 0.05 ∗∗∗p < 0.001 vs mild OSAS (Student’s t test for unpaired data). BMI = Body Mass Index; AHI = Apnea-hypopnea
index. mSO2 = mean oxygen saturation. ODI = oxygen desaturation index. ESS = Epworth sleepiness scale.
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employing the 1-way analysis of variance (ANOVA), integrated with the Bonferroni post-test. The
correlations among MMP-2, MMP-9, TIMP-1, TIMP-2, demographic characteristics, and polysomno-
graphic parameters were performed employing the linear regression test; the null hypothesis was
rejected for p values <0.05.
3. Results
In the whole group of OSAS subjects we found a significant increase in plasma concentrations of
gelatinases and their inhibitors in comparison with normal controls (Table 2). We noted also a significant
decrease in MMP-9/TIMP-1 ratio compared to normal controls but no significant variation in MMP-
2/TIMP-2 ratio (Table 2). Subdividing OSAS subjects in the two subgroups (L and H), we noted in
both subgroups a significant increase of the examined parameters in comparison with normal controls
(Table 3). We observed a significant variation of MMP-9 and TIMP-1 between the two subgroups
(Bonferroni post-test) and in fact both these parameters were significantly higher in the H subgroup
in comparison with the L subgroup of OSAS subjects (Table 3). In addition, we observed that the
MMP-9/TIMP-1 ratio is reduced only in the L subgroup compared with normal controls (Table 3)
while no statistical difference was found regarding the MMP-2/TIMP-2 ratio. About the demographic
characteristics, in the entire group of OSAS subjects we observed a positive correlation between
MMP-2 and age (r = 0.339, p < 0.05), between TIMP-2 and age (r = 0.550, p < 0.0001) and between
MMP-9 and neck circumference (r = 0.403, p < 0.05). Regarding the polysomnographic parameters
Table 2
Mean ± S.D. of gelatinase and inhibitor concentrations and their ratios in plasma of control subjects
and all OSAS patients
Control subjects All OSAS patients
MMP-9 (ng/ml) 51.55 ± 8.14 99.12 ± 15.84∗∗∗
TIMP-1 (ng/ml) 32.05 ± 4.80 67.98 ± 5.92∗∗∗
MMP-2 (ng/ml) 28.66 ± 4.15 35.78 ± 8.96∗∗∗
TIMP-2 (ng/ml) 85.67 ± 9.40 105.8 ± 9.38∗∗∗
MMP-2/TIMP-2 0.338 ± 0.059 0.337 ± 0.076
MMP-9/TIMP-1 1.652 ± 0.376 1.464 ± 0.234∗∗
∗∗p < 0.01 ∗∗∗p < 0.001 vs control subjects.
Table 3
Mean ± S.D. of gelatinase and inhibitor concentrations and their ratios in plasma of control subjects and the two subgroups
of OSAS patients, with respectively mild and severe disease
Control subjects Mild OSAS Severe OSAS F
MMP-9 51.55 ± 8.14 89.22 ± 11.07∗∗∗ 106.8 ± 14.8∗∗∗§ 169.5b
TIMP-1 32.05 ± 4.80 64.87 ± 5.53∗∗∗ 70.40 ± 5.09∗∗∗# 464.6b
MMP-2 28.66 ± 4.15 37.90 ± 10.44∗∗∗ 34.12 ± 7.39∗ 10.08b
TIMP-2 85.67 ± 9.40 104.8 ± 8.35∗∗∗ 106.6 ± 10.19∗∗∗ 42.37b
MMP-2/TIMP-2 0.338 ± 0.059 0.361 ± 0.096 0.318 ± 0.050 2.351
MMP-9/TIMP-1 1.652 ± 0.376 1.387 ± 0.228∗∗ 1.523 ± 0.225 5.065a
ap < 0.01 bp < 0.001 (ANOVA). ∗p < 0.05 ∗∗p < 0.01 ∗∗∗p < 0.001 vs control subjects (Bonferroni’s post-test). #p < 0.01 §
p < 0.001 vs mild OSAS (Bonferroni’s post-test).
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Fig. 1. Correlations between MMP-9 and polysomnographic parameters in the entire group of OSAS subjects.
(Fig. 1), we observed a positive correlation between MMP-9 and AHI value (r = 0.450, p < 0.01) and
between MMP-9 and ODI (r = 0.36, p < 0.05) and a negative correlation between MMP-9 and mean
oxygen saturation (mSO2) (r = −0.48, p < 0.001) in the whole group of OSAS subjects. No significant
correlation among MMP-2, TIMP-1, TIMP-2 and polysomnographic parameters was observed.
4. Discussion
The obtained data showed an increase in plasma concentrations of gelatinases (MMP-2 and MMP-
9) and their inhibitors (TIMP-1 and TIMP-2) in the entire group of OSAS subjects and in both the
subgroups, although in the H subgroup the values of MMP-9 and TIMP-1 were significantly higher
than in the L subgroup. While the MMP-2/TIMP-2 ratio did not discriminate the whole group and
the two subgroups of OSAS subjects compared to normal controls, the MMP-9/TIMP-1 ratio was
significantly reduced in the entire group and in the L subgroup of OSAS subjects. This behavior is
probably imputable to the fact that the percentage increase in TIMP-1, observed both in the entire
group and in the L subgroup, was surely higher if compared with the MMP-9 increase.
We retain that the behavior of the gelatinases is dependent especially on their over-production
stimulated by the hypoxia-reoxygenation events and by several cytokines, such as IL-6 and TNF-
[17, 18, 29, 36], while the trend of their tissue inhibitors might be imputable to their co-secretion or to
a compensatory effect [6]. As well as the hypoxic stress induced by OSAS promotes the synthesis of
inflammatory mediators [31, 35] involved in the development and the progression of the atherosclerotic
disease, similarly the hypoxic stress seems to be able to modify the pattern of MMPs and TIMPs itself.
The behavior of MMP-2 and MMP-9 agrees partially with the results observed by other authors [3, 9,
32, 41] while our data regarding the tissue inhibitors are different from those of others [3, 32] who did
not find any variation of these TIMPs between OSAS subjects and control groups. In agreement with
Tazaki, Ye, Feng and Volna [9, 32, 35, 41], we observed in the whole group of OSAS subjects a positive
correlation between MMP-9 and AHI, and between MMP-9 and ODI and also a negative correlation
between MMP-9 and mSO2. In this study no significant correlation among MMP-2, TIMP-1, TIMP-2
and polysomnographic parameters was demonstrated.
Only in the whole group of OSAS subjects we also observed a positive correlation between MMP-
9 and TBARS (thiobarbituric acid reactive substances) (r = 0.541, p < 0.001), between MMP-9 and
carbonyl groups (r = 0.395, p < 0.005) and between MMP-9/TIMP-1 ratio and TBARS (r = 0.472,
p < 0.0007); as it is known, TBARS reflects the lipid peroxidation while carbonyl groups express
the protein oxidation. We did not find any statistical correlation between the other parameters of the
oxidative stress (TAS, NOx) and the gelatinases or their inhibitors.
We know that OSAS is accompanied by several complications such as arterial hypertension, coronary
disease and cerebrovascular events [7, 21, 37, 39], and it should be considered if the behavior of the
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gelatinases might play a role in the development of these vascular complications. Up to now, the
literature data show a controversial relationship between gelatinases and pulse wave velocity, that
reflects arterial stiffness: in subjects with isolated systolic hypertension [40] and in subjects with
chronic kidney disease, with or without diabetes mellitus [5], a correlation between gelatinases and
arterial stiffness was observed, but not in healthy individuals [34] and in type 2 diabetic subjects [25].
In OSAS subjects it is not possible to exclude a role of the gelatinases in the development of arterial
hypertension, although in this clinical condition the increase in blood pressure is imputable especially
to the increase in sympatethic tone [5, 25, 34, 40].
Another consideration that regards the behaviour of gelatinases in OSAS subjects concerns their
role about the angiogenesis. Gelatinases activity produces elevated levels of angiostatin through the
proteolitic cleavage of plasminogen. As it is known, angiostatin inhibits endothelial cell proliferation
and migration, induces apoptosis, reduces vascular endothelial growth factor expression and decreases
eNOS activity [4]. It is possible that the influence played by the gelatinases on the angiogenesis might
contribute to the increased risk of cardiovascular events, also considering that in this preliminar study
MMP-9 and TIMP-1 clearly discriminate subjects with mild OSAS from subjects with severe OSAS,
which have an higher cardiovascular morbidity and mortality. In OSAS subjects some authors [32]
found a decrease in MMP-9 levels and activity after cPAP treatment, and others [31] noted even the
decrease of MMP-9 production by monocytes after 3 months of cPAP therapy. Recently Vuralkan [36]
demonstrated a decrease in MMP-9 levels in a group of OSAS subjects who underwent uvulopalatal
flap surgery.
Regarding the MMPs pattern in OSAS, a point that deserves to be considered is if, in this clinical
condition, MMPs may be retained a pharmacological target; we suppose that, in clinical practice,
the several molecules that act on MMPs may give possible benefits in the overall treatment of this
syndrome.
In summary, in OSAS we found an altered profile of the gelatinases and their inhibitors, and especially
we observed that MMP-9 and TIMP-1, its principal inhibitor, are significantly higher in OSAS subjects
with a severe degree of the disease in comparison with those of mild-moderate degree. In OSAS the
evaluation of these parameters may be useful thus their behavior may contribute to explain in particular
the vascular involvement that, in the course of time, accompanies this syndrome.
This research complies with the requirement for ethical publication in Clinical Hemorheology and
Microcirculation as published in Clin Hemorheol Microcirc. 2010;44(1):1-2.
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